Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram

This study has been completed.
Sponsor:
Collaborator:
AlzChem, LLC
Information provided by (Responsible Party):
Doug Kondo, University of Utah
ClinicalTrials.gov Identifier:
NCT00851006
First received: February 23, 2009
Last updated: June 19, 2013
Last verified: June 2013
  Purpose

The purpose of this study is to see if creatine, which is a naturally occurring chemical in the body, is effective for treating Major Depressive Disorder (MDD) in female teenagers. Creatine may have effects of interest in the brain. The reason for the MRI component of this study is to learn about new ways to see inside the brain. The investigators will use magnetic fields and radio waves to look at the brain and chemicals in the brain. The investigators hope that this technique will have medial use in the future.

The primary hypothesis of the study is that oral creatine supplementation will have a beneficial effect as adjunctive therapy in female adolescents with MDD who are non-responders to an adequate trial of the SSRIs Fluoxetine or Escitalopram.


Condition Intervention Phase
Major Depressive Disorder
Drug: Creatine Monohydrate
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Adjunctive Creatine Treatment for Adolescent Females With Major Depressive Disorder Who Are Non-Responders to Fluoxetine or Escitalopram: A Magnetic Resonance Spectroscopy Study

Resource links provided by NLM:


Further study details as provided by University of Utah:

Primary Outcome Measures:
  • The primary clinical outcome measure will be the change in CDRS-R; response will be defined as a > 50% decrease in CDRS-R score from baseline and a CGI improvement score of 1 or 2. [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • MRI volumetric measurements (i.e. VBM and morphometric analyses). [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Enrollment: 7
Study Start Date: April 2009
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Creatine Monohydrate
    4gm of oral creatine will be administered once per day for 8 weeks
    Other Name: CreaPure
Detailed Description:

This is an open-label clinical trial of the investigational drug creatine, for augmentation treatment of female adolescents with Major Depressive Disorder (MDD) who have failed to respond to first-line treatment with Fluoxetine or Escitalopram. Widely used by high school and college athletes in the U.S., creatine is an over-the-counter nutritional supplement with annual sales of more than $200 million. Studies in animals show that creatine improves the performance of female rats in the Porsolt Forced Swim test, which is used to predict the efficacy antidepressant compounds. Human neuroimaging studies indicate that patients with MDD have abnormal levels of high-energy phosphate metabolites in brain, primarily adenosine triphosphate (ATP) and phosphocreatine. Research has also shown that creatine supplementation induces changes in these high-energy phosphate metabolites that are associated with a positive response to antidepressants. For the proposed study, ten female adolescents between the ages of 13-18 with MDD will be recruited for participation in an open-label trial of creatine. Participants with depression will have unremitted MDD despite treatment with Fluoxetine at a dose > 40mg daily for > 4 weeks or Escitalopram at a dose of > 10 mg daily for > 4 weeks. Depressed participants will be treated with oral creatine 4gm daily for eight weeks, and will continue to take Fluoxetine or Escitalopram as prescribed. In addition, ten healthy control participants with no history of psychiatric or substance abuse disorder will be recruited. No treatment will be administered to the control participants. The primary outcome measure will be the Children's Depression Rating Scale (CDRS-R), which was used in the Treatment for Adolescents with Depression Study (TADS) clinical trial (March et al., JAMA 2004; 292(7):807-20) and the Treatment of Resistant Depression in Adolescents (TORDIA) study (Brent et al., JAMA 2008;299(8):901-13). All study participants will undergo brain scans at baseline and again after six weeks, with 31-Phosphorus Magnetic Resonance Spectroscopy (31P-MRS). The brain scans will be used to measure high-energy phosphate metabolites in the Anterior Cingulate Cortex (ACC), an anatomical region of the brain that has been implicated in MDD. 31P-MRS is a non-invasive neuroimaging technique that does not expose participants to radiation. At the magnetic field strength utilized (3T), magnetic resonance imaging is FDA-approved and has no known adverse effects. The research team will use data from 31P-MRS scans to compare levels of high-energy phosphate metabolites in MDD participants vs. healthy controls. In addition, comparison of pre- and post-treatment metabolite levels will be conducted in the MDD participants. The primary hypothesis of the study is that oral creatine will show efficacy as an augmentation treatment for female adolescents with MDD whose depression has not responded to Fluoxetine or Escitalopram. Secondary hypotheses include the following: adolescents with treatment-resistant MDD will show differences at baseline from healthy controls in high-energy phosphate metabolites in the ACC; and that brain scans in depressed adolescents who respond to creatine will show normalization of high-energy phosphate metabolites in the ACC.

  Eligibility

Ages Eligible for Study:   13 Years to 18 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Selection of Major Depressive Disorder Participants:

  • Participants must meet DSM-IV-TR criteria for Major Depressive Disorder, with current mood state depressed for > 2 weeks.
  • Participants must be females
  • Participants must be between the age of 13 and 18 years.
  • Participants must have had an adequate trial of Fluoxetine, defined as a trial of > 8 weeks of treatment, with a dose of > 40mg daily for > 4 weeks. If the participant had a trial of 40mg daily and was unable to tolerate it, a dose of 20mg for > 8 weeks is acceptable; OR
  • Participants must have had an adequate trial of escitalopram, defined as a trial of > 8 weeks of treatment, with a dose of > 20 mg daily for > 4 weeks. If the participant had a trial of 20 mg daily and was unable to tolerate it, a dose of 10 mg for > 8 weeks is acceptable.
  • Participants must have a CDRS-R score of > 40 and a CGI-S score of > 4.
  • Participants must be able to give informed consent or assent, and parent(s)/guardian(s) must be able to give informed permission for study participation.

Selection of Healthy Control Participants:

  • Participants must be females between the ages of 13 and 18 years.
  • Participants must not meet DSM-IV-TR diagnostic criteria for a psychiatric or substance abuse disorder.
  • Participants must be able to give informed consent or assent and parent(s)/guardian(s) must be able to give informed permission for study participation.

Exclusion criteria for creatine treatment study of female adolescents with MDD:

  • Adolescents with an unstable co-morbid medical, neurological, or psychiatric disorder.
  • Participants with known pre-existing renal disease.
  • Participants with proteinuria or microalbuminuria.
  • Pregnant females, nursing mothers, or females of childbearing potential who are unable or unwilling to practice birth control during the study. Participants who are of child-bearing potential must have a negative urine pregnancy test before each MRS scan.
  • Participants at high risk for suicidal behaviors, homicidal behaviors, or self-harm.
  • Participants who in the opinion of the principal investigator are unlikely to be able to comply with the study protocol.
  • Participants who meet DSM-IV-TR criteria for current substance abuse or substance dependence, with the exception of nicotine abuse or dependence.
  • Participants for whom MRS scanning is contraindicated, such as adolescents with ferromagnetic implants or claustrophobia.
  • Documented or suspected history of mental retardation (IQ < 70).
  • History of hypersensitivity to creatine.

Exclusion criteria for healthy controls:

  • Clinically significant psychiatric or substance abuse disorder.
  • Unstable medical or neurological illness.
  • Pregnant adolescents, due to the unknown effects of MRS scanning on a developing fetus.
  • Females of childbearing potential who are unable or unwilling to practice contraception during the study.
  • Positive urine pregnancy test.
  • Participants with a contraindication to MRS scanning, such as ferromagnetic implant or claustrophobia.
  • Documented or suspected history of mental retardation (IQ<70).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00851006

Locations
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84108
Sponsors and Collaborators
University of Utah
AlzChem, LLC
Investigators
Principal Investigator: Doug Kondo, MD University of Utah
  More Information

Additional Information:
Publications:
Responsible Party: Doug Kondo, MD, University of Utah
ClinicalTrials.gov Identifier: NCT00851006     History of Changes
Other Study ID Numbers: 33465
Study First Received: February 23, 2009
Last Updated: June 19, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Utah:
Depression
Females
Adolescents

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Dexetimide
Citalopram
Fluoxetine
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Serotonin Agents

ClinicalTrials.gov processed this record on July 24, 2014